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We conducted a prospective quality-of-life analysis during outpatient immunotherapy in 22 patients with progressive metastatic renal
cell carcinoma (RCC) treated with subcutaneous interferon-a2a and subcutaneous interleukin-2. Patients’ quality of life was assessed
by the European Organization for Research and Treatment of Cancer quality-of-life questionnaire QLQ-C30 before (week 0) and
once during immunotherapy (week 3). Advanced renal cancer patients completed a total of 30 questionnaires before therapy (week
0) and after 3 weeks of therapy. Their mean quality of life (global-quality-of-health status) deteriorated significantly, from 64 to 41
(Pp0.001) during the first 3 weeks after treatment initiation, due to a mean reduction in physical (from 82 to 65; Pp0.001),
emotional (from 77 to 61; Pp0.01), social (from 78 to 55; Pp0.01), and role functioning (from 82 to 58; Pp0.01). In contrast,
cognitive functioning did not differ significantly from pretreatment scores after 3 weeks of therapy. In addition, during the first 3
weeks, appetite loss (from 18 to 59; Pp0.01), fatigue (from 33 to 56; Pp0.01), nausea/vomiting (from 10 to 26; Pp0.01), sleep
disturbance (from 27 to 47; Pp0.01), diarrhoea (from five to 27; Pp0.01), and pain (from 20 to 32; Pp0.05) were significantly
increased, while quality-of-life symptoms such as dyspnoea, and constipation were not significantly influenced by therapy. Complete
response to RCC outpatient immunotherapy was associated with the most predominant reduction in functional quality of life when
compared against patients in progressive or stable disease or partial tumour response. In conclusion, quality-of-life analysis during
outpatient immunotherapy yielded modest changes in patients’ health status 3 weeks after therapy initiation. Since the rapid decline in
functional quality-of-life was associated with therapeutic efficacy, it is suggested that quality-of-life analysis might serve as an early
indicator for immunotherapy response in metastatic RCC.
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Renal cell carcinoma (RCC) accounts for 2–3% of all malignant
tumours in adults (Elson et al, 1988). Patients with untreated
metastatic RCC have an overall median survival of no more than 12
months and a 5-year survival of less than 10%.
Immunotherapy with cytokines, notably subcutaneous recom-
binant interleukin-2 (s.c. IL-2) alone or in combination with
subcutaneous recombinant interferon-a2a (s.c. IFN-a2a) at doses
far below the maximum tolerated dose, yields significant
therapeutic efficacy in RCC patients (Atzpodien et al, 1990; Sleijfer
et al, 1992). Although subcutaneous application of IL-2 and IFN-a
is associated with reduced treatment-related toxicity compared to
intravenous application, worsening of quality of life in patients
receiving systemic combination immunochemotherapy are de-
scribed by several authors (Atzpodien et al, 1995; Joffe et al, 1996).
However, validated information about the quality of life
experienced by advanced renal cancer patients receiving
IL-2/IFN-a containing therapy is hardly available.
Today, the most internationally recognised instrument for the
evaluation of patients’ quality-of-life outcome in cancer research is
the Quality of Life Questionnaire-C30 (QLQ-C30) developed by the
European Organisation for Research and Treatment of Cancer
(Aaronson et al, 1993; Biermann and Ku ¨chler, 1999).
The purpose of this study was to evaluate the quality of
life experienced by 22 patients receiving low-dose s.c. IL-2, s.c.
IFN-a2a combined with p.o. 13-cis-retinoic acid (13cRA) using the
core questionnaire of the EORTC-QLQ-C30.
PATIENTS AND METHODS
The characteristics of the study population, which consisted of 16
male and six female patients, are summarised in Table 1. At the
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ltime of therapy start, patients were between 45 and 74 years old
with a mean age of 64 years. Patient pretreatment included
radiotherapy (n¼5), chemoimmunotherapy (n¼1), and tumour
vaccine (n¼1). All patients underwent tumour nephrectomy.
Metastases localised predominantly in lung (n¼15), lymph nodes
(n¼7), bone (n¼3), liver (n¼3), and other sites (n¼9).
Inclusion and exclusion criteria
A total of 22 patients with progressive metastatic RCC were treated
with s.c. rIFN-a2a, s.c. rIL-2, and p.o. 13cRA, respectively. Since
the treatment regimen was designed to be administrated at home,
this required a selection of patients with good or fair performance
status.
This study was approved by the institutional review board
of the Medizinische Hochschule Hannover; written informed
consent was obtained from all patients prior to entry into the
study. Criteria for entry into the study were histologically
confirmed progressive and irresectable metastatic RCC; an
expected survival duration of more than 3 months; Karnofsky
performance status X80%; age between 18 and 80 years; white
blood cell count X3500ml
 1; platelet count X100000ml
 1;
haematocrit X30%; serum bilirubin and creatinine p1.25 of the
upper normal limit; no evidence of congestive heart failure, no
severe coronary artery disease, no cardiac arrhythmias, no
clinically symptomatic CNS disease or seizure disorders, no
human immunodeficiency virus infection, no evidence of chronic
active hepatitis, no concomitant corticosteroid therapy. In all
patients treated, no chemotherapy or immunomodulatory treat-
ment had been performed during the previous 4 weeks. Also,
pregnant and lactating women were excluded.
Study design
Since all treatment regimens were designed to be administrated at
home, this required selection of patients with good or fair
performance status. There was no significant difference in
distribution of known prognostic variables in those patients
compared. Treatment consisted of s.c. rIFN-a2a (5 10
6IUm
 2,
day 1, weeks 1þ4; days 1, 3, 5, weeks 2þ3; 10 10
6IUm
 2, days
1, 3, 5, weeks 5–8), s.c. rIL-2 (10 10
6IUm
 2, twice daily days
3–5, weeks 1þ4; 5 10
6IUm
 2, days 1, 3, 5, weeks 2þ3)
combined with p.o. 13cRA (20mg 3 daily) over 8 weeks.
Following week 3 quality-of-life re-evaluation, some patients
received additional i.v. 5-fluorouracil or p.o. capecitabine during
weeks 5–8. In all, 8-week treatment cycles were repeated for up to
three courses unless progression of disease occurred. If patients
achieved a complete remission in the third cycle, a fourth cycle was
added. Re-evaluation of the patients tumour status was performed
between treatment cycles. Concomitant medication was given as
needed to control adverse effects of immunochemotherapy.
Assessment of response
Response to therapy was evaluated according to World Health
Organization (WHO) criteria on intent-to-treat basis.
QLQ-C30 Questionnaire
Patients responded without help and influence to 30 items of the
core QLQ-C30 questionnaire (Aaronson et al, 1988). Among them,
28 items are scored from 1 to 4 with a lower score representing a
better quality of life; while two items (global-quality-of-health)
were scored 1–7 points with a higher score representing a better
quality of life.
The questionnaire permits the grouping of individual items into
five functional scales (physical, role, emotional, cognitive, and
social), a global-quality-of-health scale, three symptom scales
(fatigue, nausea/vomiting, and pain), and a number of single items
assessing physical symptoms common among cancer patients
(dyspnoea, sleep disturbance, appetite loss, constipation, diar-
rhoea), as well as the financial impact of the disease and treatment.
Before statistical analyses were made, the raw EORTC QLQ-C30
scores were linearly transformed to a 0–100 scales (Fayers et al,
2000). For the five functional scales, items responses were recoded,
so that a higher score represents a better level of functioning. For
the symptom-oriented scales and items, a higher score corresponds
to a higher level of symptoms. A mean change in scores of 5–10
has been found to represent ‘a little’ subjective change to patients,
whereas a change of 10–20 represents a moderate change (Osoba
et al, 1998); thus differences of 10 points and more may be
regarded as clinically significant. Each patient completed the
questionnaire once before treatment (0 week) and once during
treatment (3 weeks after therapy start).
Statistical analysis
For statistical analysis of the data, the Wilcoxon test and the
Mann–Whitney U-test were used wherever applicable.
RESULTS
A total of 22 stratified low/intermediate risk metastatic RCC
patients received s.c. rIFN-a2a, s.c. rIL-2 combined with p.o.
13cRA as home therapy.
Evaluation of questionnaires
Figure 1 illustrates that patients’ mean pretreatment global-
quality-of-health scale deteriorated significantly from 64 (week 0)
to 41 (week 3; Pp0.001).
Table 1 Patients’ characteristics
Characteristics All patients
Entered 22
Age (years)
Median 64
Range 45–74
Sex
Male 16
Female 6
Pretreatment
Tumour nephrectomy 22
Radiotherapy 5
Chemoimmunotherapy 1
Tumour vaccine 1
Metastatic sites
Lung 15
Lymph nodes 7
Bone 3
Liver 3
CNS 0
Others
a 9
Treatment response
CR 4
PR 5
SD 9
PD 4
CR¼complete responder; PR¼partial responder; SD¼patient with stable disease;
PD¼patient with progressive disease.
aIncluding local relapse, contralateral kidney,
adrenals, and pleura.
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each of the five functional scales (physical, role, cognitive,
emotional, social; Figure 1), while 3 weeks after therapy initiation,
a mean change in scores of 10 and more was found in physical
functioning (from 82 to 65; Pp0.001), emotional functioning
(from 77 to 61; Pp0.01), social functioning (from 78 to 55;
Pp0.01), and role functioning (from 82 to 58; Pp0.05).
Reduction in functional quality of life was correlated to tumour
response, albeit in a statistically insignificant manner. Thereby,
reduction was most prominent in patients with complete tumour
regression, followed by those with partial responses, with stable
disease and then those with progressive disease (Figure 2A–D).
Notably, patients with progressive disease exhibited the least
reduction in functional quality of life:
Physical functioning was decreased in complete responders
(CRs) from 83 to 53, in partial responders (PRs) from 77 to 57, in
patients with stable disease (SDs) from 83 to 69, and in progressive
disease patients (PDs) from 85 to 77, only, 3 weeks after therapy
start. Similarly, role functioning deteriorated in CRs from 79 to 29,
in PRs from 87 to 50, in SDs from 81 to 67, and in PDs from 79 to
75, only, 3 weeks after immunotherapy. Cognitive functioning was
decreased in patients with CR from 75 to 58, with PR from 97 to 83,
and with SD from 81 to 78, while PDs experienced an increase in
cognitive functioning from 92 to 100, 3 weeks after therapy
initiation. Emotional functioning deteriorated in patients with CR
from 67 to 29, with PR from 78 to 62, with SD from 81 to 67, but
was unchanged in PDs (from 79 to 79), 3 weeks after
immunotherapy start. Finally, social functioning was decreased
in CRs from 75 to 29, in PRs from 83 to 47, in SDs from 78 to 67,
and in PDs from 75 to 67, only, 3 weeks after therapy initiation.
Figure 3 demonstrates that during the first 3 weeks of IL-2 and
a-IFN-based home therapy, appetite loss (from 18 to 59; Pp0.001),
fatigue (from 33 to 56; Pp0.01), nausea/vomiting (from 10 to 26;
Pp0.01), sleep disturbance (from 27 to 47; Pp0.01), diarrhoea
(from five to 27; Pp0.01), and pain (from 20 to 32; Pp0.05) were
significantly impaired, while symptoms such as dyspnoea and
constipation were not significantly influenced by the therapy 3
weeks after therapy.
Again, PDs exhibited the least increase in symptom scales (data
not shown).
DISCUSSION
In the context of a poor prognosis for survival of advanced renal
carcinoma patients, quality-of-life assessments become an im-
portant issue for both the patient and the clinician. The current
analysis provided first information about quality of life experi-
enced by metastatic RCC patients before treatment and 3 weeks
after treatment initiation with s.c. IL-2, s.c. IFN-a2a, and p.o. 13-
cis-retinoic acid as home therapy. Our data indicated that low-dose
s.c. immunotherapy administered at home significantly reduced
patients’ global-quality-of-health from 64 to 41 (Pp0.001) and that
treatment-related changes in quality of life were mainly caused by
a decrease in physical functioning (from 82 to 65), psychological
distress (from 77 to 61), an impairment of social activities (social
functioning; from 78 to 55), and a limitation in working capacity
(role functioning; from 82 to 58), respectively. Mainly, renal
carcinoma patients suffered from clinical symptoms such as
appetite loss (from 18 to 59), fatigue (from 33 to 56), nausea/
vomiting (from 10 to 26), sleep disturbance (from 27 to 47),
diarrhoea (from five to 27), and pain (from 20 to 32).
Mean functioning scales
0
20
40
60
80
100
Week 0 82 82 86 77 78 64
Week 3 65 58 80 61 55 41
Physical Role Cognitive Emotion Social Global
c c b
aP0.05;bP0.01;cP0.001
b a
Figure 1 QLQ-C30 quality-of-life questionnaire-specific functional scales
for patients (n¼22) before (week 0) and during outpatient immunother-
apy (week 3). Higher scores represent a better level of functioning.
aPp0.05;
bPp0.01;
cPp0.001 (Wilcoxon test).
Mean functioning scales: CR
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Mean functioning scales: PR
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Mean functioning scales: SD
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Mean functioning scales: PD
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Figure 2 QLQ-C30 quality-of-life questionnaire-specific functional scales
for complete responders (CR; n¼4), partial responders (PR; n¼9);
patients with stable disease (SD; n¼9) or patients with progressive disease
(PD; n¼4) before (week 0) and during outpatient immunotherapy (week
3). Higher scores represent a better level of functioning. Comparison of
response groups was rendered statistically insignificant.
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predominant reduction in functional quality of life when compared
against PDs or SDs or PRs 3 weeks after immunotherapy initiation.
In contrast, previous quality-of-life analyses in chemotherapy-
treated advanced cancer patients often showed an improvement in
the EORTC QLQ-C30 scores during therapy (Doyle et al, 2001;
Kornblith et al, 2002). Geels et al (2000) demonstrated that in
chemotherapy-treated metastatic breast cancer patients, symptom
improvement (pain, constipation anorexia, nausea) was best in
those patients who had complete or partial responses, followed by
those with SD and then those with progressive disease; it was
therefore suggested that tumour response might be a surrogate for
symptom improvement in some cases.
The discrepancy in results of quality-of-life analysis of
immunotherapy- vs chemotherapy-treated cancer patients might
be best explained by the different modes of action of both therapy
regimens. In immunotherapy-treated patients, efficacy is mainly
attributed to patients’ immune response capacity, which is closely
associated with increased constitutional side effects, such as
appetite loss, fatigue, nausea/vomiting, diarrhoea, and pain,
leading to a decline in quality of life. There are several other
possible explanations for the present observation: these include
that patients with high disease volume may not respond to
immunotherapy; patients with disease in particular sites respond
differently to immunotherapy; dose and duration of therapy may
be different between patients.
While we hypothesised that those patients with more intact
immune functions were more likely to have a deterioration in their
quality of life than those whose immune systems could not be
properly activated by IL-2-based therapy, previous studies in
advanced renal carcinoma patients receiving inhalational IL-2-based
therapy indicated that IL-2 immunotherapies may become more
tolerable over time (Heinzer et al, 1999). Since we documented
strong therapy-related impairment of quality of life upon treatment
initiation, in future trials, quality-of-life analyses should be
documented over extended periods of time (i.e., up to 1 year) to
potentially demonstrate treatment-related effects in relation to time,
to patient tolerance, and to cumulated toxicity. Also, in the present
study, IL-2- and IFN-associated changes in quality of life were largely
overlapping, and could not be separately evaluated.
In summary, our data demonstrated significant changes in
patients’ well-being 3 weeks after outpatient immunotherapy
initiation. Since a rapid decline in functional quality of life was
associated with a good therapeutic outcome, future trials on an
extended number of advanced RCC patients receiving IL-2-based
immunotherapy in a prospectively controlled trial setting may
confirm that validated quality-of-life analyses can serve as an early
prognostic indicator for response, and potentially also for survival.
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